Pitavastin 4mg + Atorvastatin 20mg + Rosuvastatin 5mg
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypercholesterolemia
Conditions
Hypercholesterolemia
Trial Timeline
Dec 1, 2011 → Oct 1, 2013
NCT ID
NCT01660191About Pitavastin 4mg + Atorvastatin 20mg + Rosuvastatin 5mg
Pitavastin 4mg + Atorvastatin 20mg + Rosuvastatin 5mg is a approved stage product being developed by Eli Lilly for Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01660191. Target conditions include Hypercholesterolemia.
What happened to similar drugs?
20 of 20 similar drugs in Hypercholesterolemia were approved
Approved (20) Terminated (2) Active (0)
✅generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)YuhanApproved
✅colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placeboDaiichi SankyoApproved
✅colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tabletsDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01660191 | Approved | Completed |
Competing Products
20 competing products in Hypercholesterolemia